

What is claimed is:

1. 6-(1H-Indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1H-indazole hemi succinate.
2. A polymorph of the hemi succinate salt of 6-(1H-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1H-indazole characterized in that it provides an XRPD pattern comprising peaks ( $^{\circ}2\theta$ ) at about 7.2, about 13.2 and/or about 14.0.
3. A polymorph according to claim 2 characterized in that it provides an XRPD pattern comprising peaks substantially as set out in Table 4.
4. A pharmaceutical composition comprising a salt as defined in claim 1 and one or more pharmaceutically acceptable excipients.

What is claimed is:

1. A polymorph of 6-(1*H*-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole characterised in that it provides an XRPD pattern comprising peaks ( $^{\circ}2\theta$ ) at about 9.0, about 9.6, about 10.4 and/or about 12.5.
2. A polymorph according to claim 1 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 1.
3. A salt of 6-(1*H*-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole which is selected from tosylate, hemi fumarate and hemi succinate.
4. 6-(1*H*-Indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole hemi succinate.
5. A polymorph of the tosylate salt of 6-(1*H*-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole characterised in that it provides an XRPD pattern comprising peaks ( $^{\circ}2\theta$ ) at about 6.3, about 9.3, about 11.3 and/or about 12.7.
6. A polymorph according to claim 5 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 2.
7. A polymorph of the hemi fumarate salt of 6-(1*H*-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole characterised in that it provides an XRPD pattern comprising peaks ( $^{\circ}2\theta$ ) at about 6.9, about 13.8 and/or about 14.4.
8. A polymorph according to claim 7 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 3.
9. A polymorph of the hemi succinate salt of 6-(1*H*-indol-4-yl)-4-(5-([4-(1-methylethyl)-1-piperazinyl]methyl)-1,3-oxazol-2-yl)-1*H*-indazole characterised in that it provides an XRPD pattern comprising peaks ( $^{\circ}2\theta$ ) at about 7.2, about 13.2 and/or about 14.0.
10. A polymorph according to claim 9 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 4.

11. A pharmaceutical composition comprising a polymorph or salt as defined in any one of claims 1 to 10 and one or more pharmaceutically acceptable excipients.
12. A polymorph or salt as defined in any one of claims 1 to 10 for use in medical  
5 therapy.
13. A polymorph or salt as defined in any one of claims 1 to 10 for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.
- 10 14. Use of a polymorph or salt as defined in any one of claims 1 to 10 in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.
15. A method of treating a disorder mediated by inappropriate PI3-kinase activity  
15 comprising administering a safe and effective amount of a polymorph or salt as defined in any one of claims 1 to 10 to a patient in need thereof.